Rationale for and results of a phase I study of the TGF-beta 1/3 inhibitor AVID200 in subjects with myelofibrosis: MPN-RC 118 trial Meeting Abstract
| Authors: | Mascarenhas, J.; Kosiorek, H. E.; Varricchio, L.; Bhave, R.; Kuykendall, A. T.; Komrokji, R.; Gerds, A. T.; Palmer, J. M.; Gabler, A. R.; Sandy, L.; Migliaccio, A. R.; Salama, M. E.; Weinberg, R. S.; O'Connor-McCourt, M.; Tremblay, G.; Nadler, P. I.; Dueck, A. C.; Mesa, R. A.; Hoffman, R. |
| Abstract Title: | Rationale for and results of a phase I study of the TGF-beta 1/3 inhibitor AVID200 in subjects with myelofibrosis: MPN-RC 118 trial |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547200161 |
| DOI: | 10.1182/blood-2020-140830 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 6 -- Source: Wos |
